{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:07Z","timestamp":1792081507310,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-07800-x","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T07:48:45Z","timestamp":1741679325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of alternative sPD-1 isoforms reveals that ECD sPD-1 signature predicts an efficient antitumor response"],"prefix":"10.1038","volume":"8","author":[{"given":"Ping","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4603-4359","authenticated-orcid":false,"given":"Yuhong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0830-1059","authenticated-orcid":false,"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"7800_CR1","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.  EMBO J.11, 3887\u20133895 (1992).","journal-title":"EMBO J."},{"key":"7800_CR2","doi-asserted-by":"publisher","unstructured":"Shreya, M. et al. Serum biomarker panel for diagnosis and prognosis of pancreatic ductal adenocarcinomas. Front. Oncol. 11, https:\/\/doi.org\/10.3389\/fonc.2021.708963 (2021).","DOI":"10.3389\/fonc.2021.708963"},{"key":"7800_CR3","doi-asserted-by":"publisher","unstructured":"Corinna, U. et al. Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood. Cancer Immunol. Immunther. 71, https:\/\/doi.org\/10.1007\/s00262-022-03166-9 (2022).","DOI":"10.1007\/s00262-022-03166-9"},{"key":"7800_CR4","doi-asserted-by":"publisher","unstructured":"Hsiang-Yun, C. et al. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. PLoS ONE 9, https:\/\/doi.org\/10.1371\/journal.pone.0095870 (2014).","DOI":"10.1371\/journal.pone.0095870"},{"key":"7800_CR5","doi-asserted-by":"publisher","unstructured":"Chris, Y. C. et al. Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy. Front. Immunol. 14, https:\/\/doi.org\/10.3389\/fimmu.2023.1123342 (2023).","DOI":"10.3389\/fimmu.2023.1123342"},{"key":"7800_CR6","doi-asserted-by":"publisher","unstructured":"Greisen, S. R. et al. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand. J. Rheumatol. 43, https:\/\/doi.org\/10.3109\/03009742.2013.823517 (2013).","DOI":"10.3109\/03009742.2013.823517"},{"key":"7800_CR7","doi-asserted-by":"publisher","unstructured":"Bing, W. et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol. 177, https:\/\/doi.org\/10.4049\/jimmunol.177.12.8844 (2006).","DOI":"10.4049\/jimmunol.177.12.8844"},{"key":"7800_CR8","doi-asserted-by":"publisher","unstructured":"Shin, H. et al. Prognostic impact of serum soluble PD-1 and ADV score for living donor liver transplantation in patients with previously untreated hepatocellular carcinoma. Ann. Surg. Treat. Res. 102, https:\/\/doi.org\/10.4174\/astr.2022.102.1.46 (2022).","DOI":"10.4174\/astr.2022.102.1.46"},{"key":"7800_CR9","doi-asserted-by":"publisher","unstructured":"Ying, P. et al. A comprehensive profiling of soluble immune checkpoints from the sera of patients with non-small cell lung cancer. J. Clin. Lab. Anal. 36, https:\/\/doi.org\/10.1002\/jcla.24224 (2022).","DOI":"10.1002\/jcla.24224"},{"key":"7800_CR10","doi-asserted-by":"publisher","unstructured":"Anna, P. et al. Programmed death-1 receptor (PD-1) as a potential prognosis biomarker for ovarian cancer patients. Cancer Manag. Res. 12, https:\/\/doi.org\/10.2147\/cmar.S263010 (2020).","DOI":"10.2147\/cmar.S263010"},{"key":"7800_CR11","doi-asserted-by":"publisher","unstructured":"Byeong-Gon, N. et al. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma. Medicine (Baltimore) 100, https:\/\/doi.org\/10.1097\/md.0000000000025640 (2021).","DOI":"10.1097\/md.0000000000025640"},{"key":"7800_CR12","doi-asserted-by":"publisher","unstructured":"Klara, D. et al. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-\u03b3, TNF-\u03b1 and PD-1\/PD-L1 in comparison to established serum tumor markers. J. Cancer Res. Clin. Oncol. 149, https:\/\/doi.org\/10.1007\/s00432-022-04112-z (2022).","DOI":"10.1007\/s00432-022-04112-z"},{"key":"7800_CR13","doi-asserted-by":"publisher","unstructured":"Manuela, T. M. et al. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers (Basel) 12, https:\/\/doi.org\/10.3390\/cancers12020473 (2020).","DOI":"10.3390\/cancers12020473"},{"key":"7800_CR14","doi-asserted-by":"publisher","unstructured":"Steffen Filskov, S., Christina, D., Britta, W., Boe Sandahl, S. & Peter, M. J. L. C. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. Lung Cancer 100, https:\/\/doi.org\/10.1016\/j.lungcan.2016.08.001 (2016).","DOI":"10.1016\/j.lungcan.2016.08.001"},{"key":"7800_CR15","doi-asserted-by":"publisher","unstructured":"Jesper Geert, P. et al. Increased soluble PD-1 predicts response to nivolumab plus ipilimumab in melanoma. Cancers (Basel) 14, https:\/\/doi.org\/10.3390\/cancers14143342 (2022).","DOI":"10.3390\/cancers14143342"},{"key":"7800_CR16","doi-asserted-by":"publisher","unstructured":"Ryotaro, O. et al. Increased plasma soluble PD-1 concentration correlates with disease progression in patients with cancer treated with anti-PD-1 antibodies. Biomedicines 9, https:\/\/doi.org\/10.3390\/biomedicines9121929 (2021).","DOI":"10.3390\/biomedicines9121929"},{"key":"7800_CR17","doi-asserted-by":"publisher","unstructured":"Heli, V. et al. Soluble PD-1 but not PD-L1 levels predict poor outcome in patients with high-risk diffuse large B-cell lymphoma. Cancers (Basel) 13, https:\/\/doi.org\/10.3390\/cancers13030398 (2021).","DOI":"10.3390\/cancers13030398"},{"key":"7800_CR18","doi-asserted-by":"publisher","unstructured":"Christian, N., Line, O.-L., Torben, B., Steffen, H. & S\u00f8ren T, L. J. C. I. Alternative splice variants of the human PD-1 gene. Cell. Immunol. 235, https:\/\/doi.org\/10.1016\/j.cellimm.2005.07.007 (2005).","DOI":"10.1016\/j.cellimm.2005.07.007"},{"key":"7800_CR19","doi-asserted-by":"publisher","unstructured":"Eva, Z. et al. Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection. AIDS 33, https:\/\/doi.org\/10.1097\/qad.0000000000002165 (2019).","DOI":"10.1097\/qad.0000000000002165"},{"key":"7800_CR20","doi-asserted-by":"publisher","unstructured":"Ila, D. et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin. Cancer Res. 25, https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-4142 (2019).","DOI":"10.1158\/1078-0432.Ccr-18-4142"},{"key":"7800_CR21","doi-asserted-by":"publisher","unstructured":"Weiping, Z., Jedd D, W. & Lieping, C. J. S. T. M. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, https:\/\/doi.org\/10.1126\/scitranslmed.aad7118 (2016).","DOI":"10.1126\/scitranslmed.aad7118"},{"key":"7800_CR22","doi-asserted-by":"publisher","unstructured":"Lloyd, B. et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature 619, https:\/\/doi.org\/10.1038\/s41586-023-06231-0 (2023).","DOI":"10.1038\/s41586-023-06231-0"},{"key":"7800_CR23","doi-asserted-by":"publisher","unstructured":"Linda, Q. et al. The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy. Cancers (Basel) 12, https:\/\/doi.org\/10.3390\/cancers12113285 (2020).","DOI":"10.3390\/cancers12113285"},{"key":"7800_CR24","doi-asserted-by":"publisher","unstructured":"Sean J. J. et al. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. 130, https:\/\/doi.org\/10.1172\/jci133353 (2020).","DOI":"10.1172\/jci133353"},{"key":"7800_CR25","doi-asserted-by":"publisher","unstructured":"Alena, G. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. Immunology 124, https:\/\/doi.org\/10.1172\/jci73639 (2014).","DOI":"10.1172\/jci73639"},{"key":"7800_CR26","doi-asserted-by":"publisher","unstructured":"Kenneth J, O., Hyesuk, Y., Rafi, A. & Jeremy M., B. J. J. I. NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 181, https:\/\/doi.org\/10.4049\/jimmunol.181.7.4832 (2008).","DOI":"10.4049\/jimmunol.181.7.4832"},{"key":"7800_CR27","doi-asserted-by":"publisher","unstructured":"Jiaxiong, T. et al. Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML. Biomark. Res. 8, https:\/\/doi.org\/10.1186\/s40364-020-0185-8 (2020).","DOI":"10.1186\/s40364-020-0185-8"},{"key":"7800_CR28","doi-asserted-by":"publisher","unstructured":"Xiangbo, M. et al. FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells. Nature 564, https:\/\/doi.org\/10.1038\/s41586-018-0756-0 (2018).","DOI":"10.1038\/s41586-018-0756-0"},{"key":"7800_CR29","doi-asserted-by":"publisher","unstructured":"Xiaoli, H. et al. Emerging role of ubiquitination in the regulation of PD-1\/PD-L1 in cancer immunotherapy. Mol. Ther. 29, https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.032 (2021).","DOI":"10.1016\/j.ymthe.2020.12.032"},{"key":"7800_CR30","doi-asserted-by":"publisher","unstructured":"Ignacio, M. et al. CD137 (4-1BB)-based cancer immunotherapy on its 25th anniversary. Cancer Discov. 13, https:\/\/doi.org\/10.1158\/2159-8290.Cd-22-1029 (2022).","DOI":"10.1158\/2159-8290.Cd-22-1029"},{"key":"7800_CR31","doi-asserted-by":"publisher","unstructured":"Daqian, G., Xiang, A., Yu, Y., Zhuo, C. & Xiang, X. J. J. I. C. Soluble immune checkpoints in cancer: production, function and biological significance. J. Immunother. Cancer 6, https:\/\/doi.org\/10.1186\/s40425-018-0449-0 (2018).","DOI":"10.1186\/s40425-018-0449-0"},{"key":"7800_CR32","doi-asserted-by":"publisher","unstructured":"Wei, L. et al. Soluble immune checkpoints are dysregulated in COVID-19 and heavy alcohol users with HIV infection. Front. Immnol. 13, https:\/\/doi.org\/10.3389\/fimmu.2022.833310 (2022).","DOI":"10.3389\/fimmu.2022.833310"},{"key":"7800_CR33","doi-asserted-by":"publisher","unstructured":"Nianyu, L. et al. Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J. 26, https:\/\/doi.org\/10.1038\/sj.emboj.7601520 (2007).","DOI":"10.1038\/sj.emboj.7601520"},{"key":"7800_CR34","doi-asserted-by":"publisher","unstructured":"Guangbo, Z. et al. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. 123, https:\/\/doi.org\/10.1111\/j.1365-2567.2007.02723.x (2008).","DOI":"10.1111\/j.1365-2567.2007.02723.x"},{"key":"7800_CR35","doi-asserted-by":"publisher","unstructured":"Chaojia, C. et al. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8(+) T cell exhaustion and anti-PD-1 resistance. Cell Rep. Med. 5, https:\/\/doi.org\/10.1016\/j.xcrm.2024.101686 (2024).","DOI":"10.1016\/j.xcrm.2024.101686"},{"key":"7800_CR36","doi-asserted-by":"publisher","unstructured":"Christian, B., Xavier, T., Laurence, G. & Jean-Fran\u00e7ois, G. J. B. P. Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases. Biochem. Pharmacol. 209, https:\/\/doi.org\/10.1016\/j.bcp.2023.115445 (2023).","DOI":"10.1016\/j.bcp.2023.115445"},{"key":"7800_CR37","doi-asserted-by":"publisher","unstructured":"Jeannin, P. et al. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity 13, https:\/\/doi.org\/10.1016\/s1074-7613(00)00030-3 (2000).","DOI":"10.1016\/s1074-7613(00)00030-3"},{"key":"7800_CR38","doi-asserted-by":"publisher","unstructured":"Frank J. W. et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur. J. Immunol. 43, https:\/\/doi.org\/10.1002\/eji.201242529 (2013).","DOI":"10.1002\/eji.201242529"},{"key":"7800_CR39","doi-asserted-by":"publisher","unstructured":"Oaks M. K. & Hallett K. M. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J. Immunol. 164, https:\/\/doi.org\/10.4049\/jimmunol.164.10.5015 (2000).","DOI":"10.4049\/jimmunol.164.10.5015"},{"key":"7800_CR40","doi-asserted-by":"publisher","unstructured":"Kathleen, M. M. et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol. Immunother. 68, https:\/\/doi.org\/10.1007\/s00262-018-2282-1 (2018).","DOI":"10.1007\/s00262-018-2282-1"},{"key":"7800_CR41","doi-asserted-by":"publisher","unstructured":"Samali, A., Zhivotovsky, B. & Orrenius, S. Current concepts in cell toxicity. Curr. Protoc. Toxicol. Chapter 2, Unit 2 1, https:\/\/doi.org\/10.1002\/0471140856.tx0201s00 (2001).","DOI":"10.1002\/0471140856.tx0201s00"},{"key":"7800_CR42","doi-asserted-by":"publisher","unstructured":"Samuel, C. & Valerie, C. J. J. I. C. High-dimensional immune-profiling in cancer: implications for immunotherapy. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2019-000363 (2020).","DOI":"10.1136\/jitc-2019-000363"},{"key":"7800_CR43","doi-asserted-by":"publisher","unstructured":"Jason, L. & Olivera J. F. J. P. T. Current modalities in cancer immunotherapy: immunomodulatory antibodies, CARs and vaccines. Pharmacol. Ther. 178, https:\/\/doi.org\/10.1016\/j.pharmthera.2017.03.008 (2017).","DOI":"10.1016\/j.pharmthera.2017.03.008"},{"key":"7800_CR44","doi-asserted-by":"publisher","unstructured":"Matthew D, V., Tianxiang, Z. & Lieping, C. J. A. R. I. Resistance mechanisms to anti-PD cancer immunotherapy. Annu. Rev. Immunol. 40, https:\/\/doi.org\/10.1146\/annurev-immunol-070621-030155 (2022).","DOI":"10.1146\/annurev-immunol-070621-030155"},{"key":"7800_CR45","doi-asserted-by":"publisher","unstructured":"Jayne F, T., Lesley A, S., Davina, G., Sarah, B. & Matthew R. S. J. T. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, https:\/\/doi.org\/10.1186\/1745-6215-8-16 (2007).","DOI":"10.1186\/1745-6215-8-16"},{"key":"7800_CR46","doi-asserted-by":"publisher","unstructured":"Sara, B., Gerta, R. & Guido, S. J. E. B. M. H. How to perform a meta-analysis with R: a practical tutorial. Evid. Based Mental Health 22, https:\/\/doi.org\/10.1136\/ebmental-2019-300117 (2019).","DOI":"10.1136\/ebmental-2019-300117"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07800-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07800-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07800-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T10:41:12Z","timestamp":1741862472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07800-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7800"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-07800-x","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"406"}}